Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, R. B.
Right arrow Articles by Pienta, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, R. B.
Right arrow Articles by Pienta, K. J.
[Cancer Research 64, 9209-9216, December 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

Lessons from a Rapid Autopsy Program

Rajal B. Shah1,3, Rohit Mehra1, Arul M. Chinnaiyan1,3, Ronglai Shen4, Debashis Ghosh4, Ming Zhou1, Gary R. MacVicar2, Soorynarayana Varambally1, Jason Harwood1, Tarek A. Bismar5, Robert Kim5, Mark A. Rubin5,6,7 and Kenneth J. Pienta2,3

Departments of 1 Pathology, 2 Medical Oncology, 3 Urology, and 4 Biostatistics, University of Michigan School of Medicine, Ann Arbor, Michigan; 5 Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts; 6 Department of Pathology, Dana Farber Cancer Institute, Boston, Massachusetts; and 7 Department of Pathology, Harvard Medical School, Boston, Massachusetts

Understanding the biology of prostate cancer metastasis has been limited by the lack of tissue for study. We studied the clinical data, distribution of prostate cancer involvement, morphology, immunophenotypes, and gene expression from 30 rapid autopsies of men who died of hormone-refractory prostate cancer. A tissue microarray was constructed and quantitatively evaluated for expression of prostate-specific antigen, androgen receptor, chromogranin, synaptophysin, MIB-1, and {alpha}-methylacylCoA-racemase markers. Hierarchical clustering of 16 rapid autopsy tumor samples was performed to evaluate the cDNA expression pattern associated with the morphology. Comparisons were made between patients as well as within the same patient. Metastatic hormone-refractory prostate cancer has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as to designing therapeutic targets for advanced disease.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
L. Zhao, B. Y. Lee, D. A. Brown, M. P. Molloy, G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, W. Kaplan, S. N. Breit, et al.
Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
Cancer Res., October 1, 2009; 69(19): 7696 - 7703.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Pu, J. Collazo, E. Jones, D. Gayheart, S. Sakamoto, A. Vogt, B. Mitchell, and N. Kyprianou
Dysfunctional Transforming Growth Factor-{beta} Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model
Cancer Res., September 15, 2009; 69(18): 7366 - 7374.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. P. Steinkamp, O. A. O'Mahony, M. Brogley, H. Rehman, E. W. LaPensee, S. Dhanasekaran, M. D. Hofer, R. Kuefer, A. Chinnaiyan, M. A. Rubin, et al.
Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
Cancer Res., May 15, 2009; 69(10): 4434 - 4442.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells
Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Wang, P. Nangia-Makker, L. Tait, V. Balan, V. Hogan, K. J. Pienta, and A. Raz
Regulation of Prostate Cancer Progression by Galectin-3
Am. J. Pathol., April 1, 2009; 174(4): 1515 - 1523.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. G. Bedolla, Y. Wang, A. Asuncion, K. Chamie, S. Siddiqui, M. M. Mudryj, T. J. Prihoda, J. Siddiqui, A. M. Chinnaiyan, R. Mehra, et al.
Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases
Clin. Cancer Res., February 1, 2009; 15(3): 788 - 796.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Tsuji, S. Ibaragi, K. Shima, M. G. Hu, M. Katsurano, A. Sasaki, and G.-f. Hu
Epithelial-Mesenchymal Transition Induced by Growth Suppressor p12CDK2-AP1 Promotes Tumor Cell Local Invasion but Suppresses Distant Colony Growth
Cancer Res., December 15, 2008; 68(24): 10377 - 10386.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
O. A. O'Mahony, M. P. Steinkamp, M. A. Albertelli, M. Brogley, H. Rehman, and D. M. Robins
Profiling Human Androgen Receptor Mutations Reveals Treatment Effects in a Mouse Model of Prostate Cancer
Mol. Cancer Res., November 1, 2008; 6(11): 1691 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. D. Martinez, R. J. Jasavala, I. Hinkson, L. D. Fitzgerald, J. S. Trimmer, H.-J. Kung, and M. E. Wright
RNA Editing of Androgen Receptor Gene Transcripts in Prostate Cancer Cells
J. Biol. Chem., October 31, 2008; 283(44): 29938 - 29949.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F.-M. Lin, C.-H. Tsai, Y.-C. Yang, W.-C. Tu, L.-R. Chen, Y.-S. Liang, S.-Y. Wang, L.-F. Shyur, S.-C. Chien, T.-L. Cha, et al.
A Novel Diterpene Suppresses CWR22Rv1 Tumor Growth In vivo through Antiproliferation and Proapoptosis
Cancer Res., August 15, 2008; 68(16): 6634 - 6642.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Chu, C.-J. Cheng, X. Ye, Y.-C. Lee, A. J. Zurita, D.-T. Chen, L.-Y. Yu-Lee, S. Zhang, E. T. Yeh, M. C-T. Hu, et al.
Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone
Mol. Cancer Res., August 1, 2008; 6(8): 1259 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al.
Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer
Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Montgomery, E. A. Mostaghel, R. Vessella, D. L. Hess, T. F. Kalhorn, C. S. Higano, L. D. True, and P. S. Nelson
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
Cancer Res., June 1, 2008; 68(11): 4447 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mehra, S. A. Tomlins, J. Yu, X. Cao, L. Wang, A. Menon, M. A. Rubin, K. J. Pienta, R. B. Shah, and A. M. Chinnaiyan
Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer
Cancer Res., May 15, 2008; 68(10): 3584 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. E. Frigo and D. P. McDonnell
Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation
Mol. Cancer Ther., March 1, 2008; 7(3): 659 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Najy, K. C. Day, and M. L. Day
ADAM15 Supports Prostate Cancer Metastasis by Modulating Tumor Cell-Endothelial Cell Interaction
Cancer Res., February 15, 2008; 68(4): 1092 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S.-L. Lin, D. Chang, A. Chiang, and S.-Y. Ying
Androgen receptor regulates CD168 expression and signaling in prostate cancer
Carcinogenesis, February 1, 2008; 29(2): 282 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Sterbis, C. Gao, B. Furusato, Y. Chen, S. Shaheduzzaman, L. Ravindranath, D. J. Osborn, I. L. Rosner, A. Dobi, D. G. McLeod, et al.
Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival
Clin. Cancer Res., February 1, 2008; 14(3): 758 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. A. Albertelli, O. A. O'Mahony, M. Brogley, J. Tosoian, M. Steinkamp, S. Daignault, K. Wojno, and D. M. Robins
Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice
Hum. Mol. Genet., January 1, 2008; 17(1): 98 - 110.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. R. Setlur, T. E. Royce, A. Sboner, J.-M. Mosquera, F. Demichelis, M. D. Hofer, K. D. Mertz, M. Gerstein, and M. A. Rubin
Integrative Microarray Analysis of Pathways Dysregulated in Metastatic Prostate Cancer
Cancer Res., November 1, 2007; 67(21): 10296 - 10303.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mehra, B. Han, S. A. Tomlins, L. Wang, A. Menon, M. J. Wasco, R. Shen, J. E. Montie, A. M. Chinnaiyan, and R. B. Shah
Heterogeneity of TMPRSS2 Gene Rearrangements in Multifocal Prostate Adenocarcinoma: Molecular Evidence for an Independent Group of Diseases
Cancer Res., September 1, 2007; 67(17): 7991 - 7995.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Shen and C. Abate-Shen
Pten Inactivation and the Emergence of Androgen-Independent Prostate Cancer
Cancer Res., July 15, 2007; 67(14): 6535 - 6538.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Chen, X.-C. Ye, K. Chu, N. M. Navone, E. H. Sage, L.-Y. Yu-Lee, C. J. Logothetis, and S.-H. Lin
A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6544 - 6548.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. D. Loberg, D. A. Bradley, S. A. Tomlins, A. M. Chinnaiyan, and K. J. Pienta
The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
CA Cancer J Clin, July 1, 2007; 57(4): 225 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Isayeva, D. Chanda, L. Kallman, I.-E. A. Eltoum, and S. Ponnazhagan
Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model
Cancer Res., June 15, 2007; 67(12): 5789 - 5797.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Tamura, M. Furihata, T. Tsunoda, S. Ashida, R. Takata, W. Obara, H. Yoshioka, Y. Daigo, Y. Nasu, H. Kumon, et al.
Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles
Cancer Res., June 1, 2007; 67(11): 5117 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang
Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption
Cancer Res., April 15, 2007; 67(8): 3646 - 3653.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al.
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. I. Scher, M. Warren, and G. Heller
The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer
Clin. Cancer Res., March 1, 2007; 13(5): 1488 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S.-L. Lin, D. Chang, and S.-Y. Ying
Hyaluronan stimulates transformation of androgen-independent prostate cancer
Carcinogenesis, February 1, 2007; 28(2): 310 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer, M. A. Rubin, and M. L. Day
Elevated E2F1 Inhibits Transcription of the Androgen Receptor in Metastatic Hormone-Resistant Prostate Cancer
Cancer Res., December 15, 2006; 66(24): 11897 - 11906.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Pootrakul, R. H. Datar, S.-R. Shi, J. Cai, D. Hawes, S. G. Groshen, A. S. Lee, and R. J. Cote
Expression of Stress Response Protein Grp78 Is Associated with the Development of Castration-Resistant Prostate Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 5987 - 5993.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Vessella and E. Corey
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. V. Litvinov, D. J. Vander Griend, L. Antony, S. Dalrymple, A. M. De Marzo, C. G. Drake, and J. T. Isaacs
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
PNAS, October 10, 2006; 103(41): 15085 - 15090.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Dehm and D. J. Tindall
Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells
J. Biol. Chem., September 22, 2006; 281(38): 27882 - 27893.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Axelrod, D. E. Axelrod, and K. J. Pienta
From the Cover: Evolution of cooperation among tumor cells
PNAS, September 5, 2006; 103(36): 13474 - 13479.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Perner, F. Demichelis, R. Beroukhim, F. H. Schmidt, J.-M. Mosquera, S. Setlur, J. Tchinda, S. A. Tomlins, M. D. Hofer, K. G. Pienta, et al.
TMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer.
Cancer Res., September 1, 2006; 66(17): 8337 - 8341.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-Y. Park, Y.-J. Kim, A. C. Gao, J. L. Mohler, S. A. Onate, A. A. Hidalgo, C. Ip, E.-M. Park, S. Y. Yoon, and Y.-M. Park
Hypoxia increases androgen receptor activity in prostate cancer cells.
Cancer Res., May 15, 2006; 66(10): 5121 - 5129.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. A. Gomez, A. de las Pozas, and C. Perez-Stable
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1216 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Varghese, S. D. Rabkin, P. G. Nielsen, W. Wang, and R. L. Martuza
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
Clin. Cancer Res., May 1, 2006; 12(9): 2919 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Han, H. Xie, Q. Chen, and J.-T. Zhang
Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}.
Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wallner, J. Dai, J. Escara-Wilke, J. Zhang, Z. Yao, Y. Lu, M. Trikha, J. A. Nemeth, M. H. Zaki, and E. T. Keller
Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice.
Cancer Res., March 15, 2006; 66(6): 3087 - 3095.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res., March 15, 2006; 12(6): 1665 - 1671.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo, and S. P. Balk
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
Cancer Res., March 1, 2006; 66(5): 2815 - 2825.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Kitagawa, J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. Keller
Vascular Endothelial Growth Factor Contributes to Prostate Cancer-Mediated Osteoblastic Activity
Cancer Res., December 1, 2005; 65(23): 10921 - 10929.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. W. Ross, S. Halabi, S.-S. Ou, B. R. Rajeshkumar, B. A. Woda, N. J. Vogelzang, E. J. Small, M.-E. Taplin, and P. W. Kantoff
Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer--A Cancer and Leukemia Group B Study
Clin. Cancer Res., November 15, 2005; 11(22): 8109 - 8113.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher and C. L. Sawyers
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
J. Clin. Oncol., November 10, 2005; 23(32): 8253 - 8261.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Pulukuri, C. S. Gondi, S. S. Lakka, A. Jutla, N. Estes, M. Gujrati, and J. S. Rao
RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in Vivo
J. Biol. Chem., October 28, 2005; 280(43): 36529 - 36540.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller
Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases through a Dual Mechanism
Cancer Res., September 15, 2005; 65(18): 8274 - 8285.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. I. Scher, M. J. Morris, W. K. Kelly, L. H. Schwartz, and G. Heller
Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards
Clin. Cancer Res., July 15, 2005; 11(14): 5223 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. J. Dimitroff, L. Descheny, N. Trujillo, R. Kim, V. Nguyen, W. Huang, K. J. Pienta, J. L. Kutok, and M. A. Rubin
Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells
Cancer Res., July 1, 2005; 65(13): 5750 - 5760.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer
{alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.